No 04 2019

Beactica Therapeutics has selected BEA-28 as a preclinical candidate in its TEAD program, which aims to develop new therapies for aggressive, hard-to-treat solid tumors, including cancers that have become resistant to existing treatments.

AstraZeneca has opened its newest global strategic R&D center in Kendall Square, Cambridge, Massachusetts. It is part of a USD 1 billion investment that will grow the company's workforce in the state by more than 50%.

Boehringer Ingelheim's survodutide, licensed from Danish Zealand Pharma, met both co-primary endpoints in the Phase III SYNCHRONIZE-2 trial in people with obesity or overweight and type 2 diabetes, with weight loss of up to 13.1% after 76 weeks versus 3.1% on placebo.

The US FDA has extended its review of Novo's Biologics License Application for denecimig in haemophilia A, citing ongoing remediation work at a manufacturing facility. No new timeline for a decision has been communicated.

Lundbeck has presented Phase Ib results for its oral drug candidate Lu AF28996 in advanced Parkinson's disease and has randomized the first patient in the Phase II DARE2 trial.

As an NLS Member, you and your colleagues get discounted tickets to selected life science events. This fall, members can save on Health Design in Finland, FHIM in China, and BIO-Europe in Germany.

The Nobel Assembly at Karolinska Institutet has decided to award the 2026 Nobel Prize in Physiology or Medicine to Karl Deisseroth, Peter Hegemann and Georg Nagel for their discoveries concerning light-gated ion channels and optogenetics.